drugset / Trial / NCT00273299

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

NCT00273299

Phase 3 Completed 607 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared to the monotherapy without producing an unacceptable adverse event profile.

Timeline

Start
2005-11
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 25 mg
Subject Valsartan Small molecule 320 mg

Indications